- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02128919
Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic (TDCSSCHIZ)
This is a study of the effects of tDCS on smoking, craving for cigarettes, cognition, and psychiatric symptoms in schizophrenic patients who are current smokers or have a history of regular cigarette smoking. It assesses smoking with CO monitoring, nicotine and nicotine levels, and craving with QSU scale and response to craving slides. Cognition is measured by MCCB, symptoms are measured by PANSS and hallucination scale.
This is a double-blind sham-controlled study with active tDCS 2ma or 20 minutes over 5 days, and sham tDCS for 40 seconds on each sham occasion.
연구 개요
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
New York
-
Orangeburg, New York, 미국, 10962
- Nathan Kline Institute for Psychiatric Research
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Diagnosis of schizophrenia spectrum disorder History of cigarette smoking
Exclusion Criteria:
- Seizure disorder or current treated neurological illness Current Acute exacerbation of psychotic state
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Active tDCS
tDCS 2 ma for 20 minutes with anode at DLPFC once a day for 5 days
|
Transcranial Direct Current Stimulation
|
가짜 비교기: Sham tDCS
tDCS 2 ma for 40 seconds with anode at DLPFC for 5 days
|
Transcranial Direct Current Stimulation
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Change From Baseline in Cigarette Craving
기간: Baseline and after 5 tDCs sessions (mean time 8.7[SD 2.7] days after basleine)
|
The Brief Questionnaire on Smoking Urges (QSU-Brief) was used to measure cigarette cravings.
Scores ranged from a minimum of 1 ("Strongly Disagree") to a maximum of 7 ("Strongly Agree") and were determined by self-reported responses to 10 statements about having cravings for smoking.
Scores closer to 1 after treatment would indicate a better outcome.
Responses to each of the 10 items in the scale were summed for one total score.
With 10 items on this scale with a range of scores from 1 to 7, on each occasion of rating the minimum score would be 7 and the maximum score would be 70.
|
Baseline and after 5 tDCs sessions (mean time 8.7[SD 2.7] days after basleine)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Change From Baseline in Cognitive Performance
기간: Baseline and 1-3 days (mean 1.8 [SD 1.4] days after 5 tDCS sessions( mean 8.7 days after baseline)
|
The MATRICS Consensus Cognitive Battery (MCCB) was used to measure cognitive performance.
Seven Domain scores and a Composite score are calculated by the proprietary MCCB Computer Scoring Program from raw scores on 10 individually administered subtests.
We used the revised MCCB program (beta version) which allows for calculation of Domain and Composite scores with missing data.
The Domain T-scores are percentile-ranked and range from <20 (<0.1 percentile) to >80 (>99.9 percentile).
The Composite scores are also percentile-ranked and range from <213 (T<20, <0.1 percentile) to >487 (T>80, >99.9 percentile).
Higher scores after baseline represent better outcomes.
Here we report difference scores from post-treatment and baseline with positive difference scores representing better outcomes.
|
Baseline and 1-3 days (mean 1.8 [SD 1.4] days after 5 tDCS sessions( mean 8.7 days after baseline)
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Change From Baseline in Psychiatric Symptoms
기간: Baseline and after 5 tDCS sessions
|
The Positive and Negative Syndrome Scale (PANSS) was used to measure psychiatric symptoms.
Item scores ranged from 1 (Absent) to 6 (Severe) for symptoms on the Positive Scale (total subscale range: 7-42), the Negative Scale (total subscale range: 7-42), and the General Psychopathology Scale (total subscale range:16-96).
All three subscales were summed for the PANSS total score (total scale range: 30-180).
Scores closer to 30 after baseline represented better outcomes.
Here we report difference scores from post-treatment and baseline with negative difference scores representing better outcomes.
|
Baseline and after 5 tDCS sessions
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Robert C Smith, MD, Nathsan Kline Institute for Psychiatric Research
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
tDCS에 대한 임상 시험
-
Hôpital le Vinatier완전한정신 분열증 | 청각적 환각프랑스, 튀니지
-
Universidad de AlmeriaSecretaría General de Universidades, Investigación y Tecnología, Junta de Andalucía,...초대로 등록
-
Northeastern UniversityMassachusetts General Hospital; National Institute on Aging (NIA)알려지지 않은
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)완전한
-
Charite University, Berlin, Germany완전한